Get the Stockscreener App
4.44
1.99%
-0.09
Pre-market:
4.38
-0.06
-1.35%
Alumis Inc stock is traded at $4.44, with a volume of 769.17K.
It is down -1.99% in the last 24 hours and up +3.26% over the past month.
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.
See More
Previous Close:
$4.53
Open:
$4.53
24h Volume:
769.17K
Relative Volume:
1.19
Market Cap:
$430.14M
Revenue:
-
Net Income/Loss:
$-238.77M
P/E Ratio:
-0.1656
EPS:
-26.808
Net Cash Flow:
$-216.62M
1W Performance:
+10.45%
1M Performance:
+3.26%
6M Performance:
-34.99%
1Y Performance:
-56.85%
1-Day Range:
$4.275
$4.66
1-Week Range:
$3.965
$4.6965
52-Week Range:
$2.7601
$13.11
Alumis Inc Stock (ALMS) Company Profile
Name
Alumis Inc
Sector
Industry
Phone
650-231-6625
Address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
4.44 | 471.41M | 0 | -238.77M | -216.62M | -26.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Initiated | Wells Fargo | Overweight |
| Jun-10-25 | Resumed | Guggenheim | Buy |
| Jan-30-25 | Initiated | Oppenheimer | Outperform |
| Oct-31-24 | Initiated | Robert W. Baird | Outperform |
| Oct-17-24 | Initiated | H.C. Wainwright | Buy |
| Jul-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-23-24 | Initiated | Guggenheim | Buy |
| Jul-23-24 | Initiated | Leerink Partners | Outperform |
| Jul-23-24 | Initiated | Morgan Stanley | Overweight |
View All
Alumis Inc Stock (ALMS) Latest News
Pattern recognition hints at Alumis Inc. upsideBuy Signal & Weekly Breakout Watchlists - newser.com
Statistical indicators supporting Alumis Inc.’s strengthQuarterly Portfolio Report & Expert Approved Momentum Ideas - newser.com
Is Alumis Inc. still worth holding after the dipWeekly Market Outlook & Momentum Based Trading Ideas - newser.com
Using Bollinger Bands to evaluate Alumis Inc.Portfolio Value Summary & AI Enhanced Market Trend Forecasts - newser.com
Trend analysis for Alumis Inc. this weekWall Street Watch & Long-Term Capital Growth Strategies - newser.com
Is Alumis Inc. stock poised for growthDollar Strength & Short-Term Trading Alerts - newser.com
Analyzing recovery setups for Alumis Inc. investorsTrade Performance Summary & Low Drawdown Investment Ideas - newser.com
Will Alumis Inc. stock recover after recent dropIndex Update & Precise Buy Zone Tips - newser.com
Developing predictive dashboards with Alumis Inc. dataJuly 2025 Outlook & Short-Term Trading Alerts - newser.com
Is Alumis Inc. stock overvalued by current metricsInsider Buying & Short-Term High Return Ideas - newser.com
What analysts say about Alumis Inc stockVolume Spike Alerts & Expert-Backed Recommendations That Deliver - earlytimes.in
Alumis (NASDAQ:ALMS) Earns Sell (E+) Rating from Weiss Ratings - MarketBeat
Following a 56% Decline Over Last Year, Recent Gains May Please Alumis Inc. (NASDAQ:ALMS) Institutional Owners - 富途牛牛
Alumis Insiders Still US$77k Away From Original Investment Value - simplywall.st
Sector ETF performance correlation with Alumis Inc.Market Performance Summary & Technical Confirmation Trade Alerts - newser.com
What moving averages say about Alumis Inc.Weekly Earnings Recap & AI Driven Stock Price Forecasts - newser.com
What analyst consensus says on Alumis Inc. stockWeekly Profit Recap & Pattern Based Trade Signal System - newser.com
Alumis Inc. (NASDAQ:ALMS) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
How to monitor Alumis Inc. with trend dashboardsPortfolio Update Summary & Advanced Swing Trade Entry Plans - newser.com
Analyzing net buyer seller activity in Alumis Inc.Rate Cut & Real-Time Volume Analysis Alerts - newser.com
What Is the Future of Sri Chakra Cement Limited Stock Expert Projections ExplainedMomentum Stock Picks & Affordable Market Insights - earlytimes.in
Is Alumis Inc a good long term investmentEarnings Miss Alerts & Learn to Pick Stocks in Under 10 Minutes - earlytimes.in
Alumis Inc Stock (ALMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alumis Inc Stock (ALMS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tananbaum James B. | Director |
May 06 '25 |
Buy |
4.34 |
20,000 |
86,800 |
4,247,670 |
| Foresite Labs, LLC | 10% Owner |
May 02 '25 |
Buy |
4.62 |
25,000 |
115,500 |
4,227,670 |
| Foresite Labs, LLC | 10% Owner |
May 06 '25 |
Buy |
4.34 |
20,000 |
86,800 |
4,247,670 |
| Foresite Capital Management VI | 10% Owner |
May 02 '25 |
Buy |
4.62 |
25,000 |
115,500 |
4,227,670 |
| Foresite Capital Management VI | 10% Owner |
May 06 '25 |
Buy |
4.34 |
20,000 |
86,800 |
4,247,670 |
| AKKARAJU SRINIVAS | Director |
May 05 '25 |
Buy |
4.67 |
160,370 |
749,676 |
3,586,788 |
| AKKARAJU SRINIVAS | Director |
May 02 '25 |
Buy |
4.55 |
159,920 |
727,636 |
3,426,418 |
| Colowick Alan | Director |
Apr 01 '25 |
Buy |
6.97 |
16,104 |
112,309 |
16,104 |
| Colowick Alan | Director |
Apr 02 '25 |
Buy |
7.49 |
2,300 |
17,235 |
18,404 |
| Babler Martin | President, CEO and Chairman |
Apr 01 '25 |
Buy |
6.44 |
15,650 |
100,733 |
106,454 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):